|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
|
|
|
Item 8.01 |
Other Events.
|
Item 9.01 |
Financial Statements and Exhibits.
|
Exhibit
Number
|
Description
|
|
Slide deck presentation
|
||
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL Document)
|
PDS BIOTECHNOLOGY CORPORATION
|
|
Date: August 10, 2022
|
By: /s/ Frank Bedu-Addo, Ph.D.
|
Name: Frank Bedu-Addo, Ph.D.
|
|
Title: President and Chief Executive Officer
|
SCV.G_X6/K/=X?\ OV*=_P +&UGC#P_]^Q7*]?K0
M&Q3#V<>QU?\ PLC6O^>D/_?H4T_$?63_ ,M(<_\ 7,5S'OFDIB]G'L=1_P +
M*UH9&^'_ +]"E_X65K7_ #TA_P"_0KE>#3 W^-9UOX?TR%2JVV!_UU?_ !KHY,S1 GTJ@T(VD]#4\S[FM/#4
M%IR+[D9MCX/TFUD>6*VV%N3^]?\ QHN/#.E3, L8%*+D_6E%N]C1R:2F .]4[@E#K2F;RQCO4,CEN33-HQUN+)=.]20W"[?FZU6YI&6F6
MXHGDN/W@*\8J5KI#%G/S51HIBY$)(QI2H4Z,5"G&R)_P"T)O4?E2?;I?;\J@VTE!ORHG^V2>WY
M4UKR1CU'Y5%2,*86)?M3^H_*FFY<^GY5%10%D2_:7]ORIK7#Y[4RB@+)'JS=
M33*=GYC17AG.-H%%% !1113 =1TXHI:0!2@TE% QZTZFK3J "BBB@84444$A
M112FJ0"4444P"G%:;3A0 +TI:** "E6DHH)'4M(#3ATI#Z" THI#2K3!CQ10
MO2EIDL*G=J*!"#O3\4W%/IL!E+BEVTM,8T4
M\4E*M.P"_P 5/!IM+Z46$.%&*2E6D2.'2E/MTI.U*#BF@%I< M66&%E;>,;^@K)T^U)S(
M#@5HR>9&ID8!L#BI//J;Z%6:)-,B9%^_X0/0F
M_P"7'_R-)_\ %4UO >A?\^/_ )&D_P#BJZ(CO36^:ES/N'LH?RHYL^ M"_Y\
M?_(TG_Q5)_P@6A?\^/\ Y&D_^*KHZ:11S/N/V -!_P"?'_R-)_\ %4G_ @&
M@_\ /A_Y&D_^*KHZ0BCFEW#V<.R.<_X5_H'_ #X?^1I/_BJ0_#_0?^?#_P C
M2?\ Q5=%13YGW'[.'\J.;/P_T#_GP_\ (TG_ ,53?^%?Z!_SX?\ D:3_ .*K
MI,4TT>'S_RX
M?^1I/_BJ9_PKSP__ - __P C2?\ Q5=+0:.9]PY(]CF_^%>>'_\ H'_^1I/_
M (JD_P"%>^'_ /H'_P#D:3_XJNCHHYI=P]G#LQS?_ K_ $#_ )\/_(TG_P 53?\ A7^@_P#/A_Y&D_\ BJZ0
MBD(S1S/N/ECV.;_X5_H'_/A_Y&D_^*H/P_T'_GP_\C2?_%5T5%/F?<7+'LCI]*8Q:2E^E%,04'BDHW4P'4E%+UH&)3
MA3:7)JA"T444A!124M(!5:E/K3: W..U,!]*M)M]*+ZXK,'39H1MVJ82E.E
M4UD^4$=$-IZUT-JCVA4
M-QC]:BM\QXQ5/Q-JDEO99C;$IZ4[J.H.53$R5-LI^.]0A984R#.?Y5AV+22E
M?2O2=/\ V5_B5XD\#KXZ72X)O#_V)]0^U->Q!O)12S-L+;LX4\8S7%Z?;B).
M%J&^9W/>J8>6"HQA);FUH\ *C?S6AYB6I8EMJBO4/^&5_B58>&VUQ]#C>P2V
M^UDPW<3N8]N[(0-DG'8#->62V2WT$M4)^S&1BYMI1RT#-W&.5)
MY(R.2I)\*T?5[S0=4L]2T^X>UOK299X)XSAHW4@JP^A%?IE\?+6T^-7[)=WK
MGEA';28?$$'&3$Z1B5A_WP9$_$UE;V4E;9GK4ZCS/"SC5UJ05T^Z/S3T'/\
M;FG_ /7Q'_Z$*_4?]JWXH:Y\(OA2=?\ #TD$>H?;H;?=<1"1=K!L\'Z"ORWT
M/G7-/_Z^(_\ T(5^C?[?G_) V_["MM_)ZJJKSBF1EDI0PN(E%V:2_4^8?^&]
M/BO_ ,_>E?\ @ O^-7=+_;_^)]G
0ML' VJ%Z[AUQ7J7@W_D3]#_
M .O"#_T6M>:_$C]I+3OAOXLN-"N=%NKR6%$:U5*O[*'PP5E^I]:_\$WO^2I>)_P#L#?\ M>.O
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M1-]JED1OV4?&UOXA^&\.CF5?[0TAFB>+/S&-F+(
MWTY(_"ND^*'P)\.?%6ZM[S43<6E_"GEBYM& 9DSG:P((.,G'UK",E2JMR.Z=
M-XC#14/(_/NOO_\ 9OU6/5?@WX>,9R;>-[=_9E&_^"?/C+Q-X=TO5X/$>A10:A:Q7<<